Research Study Background
On 11th December 2017 FDA approves Medimetriks Xepi (ozenoxacin) Cream, 1% for the treatment of Impetigo for pediatric patients caused due to Staphylococcus aureus or Streptococcus pyogenes.
Impetigo also known as school sores is a communicable skin infectious disease which is most common among childrens than adults in between 2 and above age group. It is estimated that in U.S. impetigo account for approximately 10% of skin problems in paediatric.
Finally, USA market populate with one more treatment option for Impetigo called Xepi is a quinolone antimicrobial that represents a novel and potentially important therapy for childrens and adults.
Xepi got accelerated approval was on the basis of two multi-center, randomized, double-blind clinical trials where Xepi has shown Overall Response Rate (ORR) (90.8%) in patients with impetigo.
1. Study was conducted to understand initial social media reaction on Xepi where total 52 online posts were analysed by our subject matter experts.
2. Study monitoring period was considered from 1st May – 25th Oct 2017.
Sentiment Analysis on Xepi Drug Approval
Positive: Health Care provider seems to positive and happy on approval of Xepi – “Ozenoxacin is a TOPICAL fluoroquinolone for impetigo. Covers MRSA too! WOW!”- HCP (RX_ED)
Neutral: Majority of people were either neutral or positive about the approval, and found sharing the information on social media platform- “Xepi Receives FDA Approval to Treat Impetigo”- News (PTJOURNAL780)